INCY Incyte Corp.
$126.75
Incyte Corp. (INCY) is expected to report earnings on November 2, 2026, before the market open. The consensus earnings estimate is a loss of $3.58 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +6.5% since its last earnings release on July 28, 2026.
Incyte Beat Expectations, Raises Guidance to be Closer to Estimates
Tuesday, July 28, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 2
Monday · 7:00 AM ET
Earnings Whisper
-
vs ($3.58)
(GAAP)
Rev est $1.47B
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP
$124.53
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Incyte Corp.
Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology.
Sector
Healthcare
Industry
Biotechnology